Literature DB >> 2545892

mRNA expression of transforming growth factor alpha in human breast carcinomas and its activity in effusions of breast cancer patients.

F Ciardiello1, N Kim, D S Liscia, C Bianco, R Lidereau, G Merlo, R Callahan, J Greiner, C Szpak, W Kidwell.   

Abstract

Transforming growth factor alpha (TGF alpha) mRNA expression was measured by Northern blot analysis in 18 human, primary, infiltrating, ductal breast carcinomas. Expression of a 4.8-kilobase TGF alpha mRNA transcript was detected in nine of 18 tumors. No evidence was observed of any gross amplifications or major rearrangements of the TGF alpha gene in the breast carcinoma specimens. Biologically active and immunoreactive TGF alpha was measured in the pleural effusions or in the ascitic fluids from 37 noncancer and 63 cancer patients. The TGF alpha activity detected ranged from 0.2 to 26 ng/mL in most effusions from both groups. However, 29 of 63 (46%) of the effusions from cancer patients exhibited TGF alpha levels that were 6 ng/mL or higher, whereas only seven of 37 (19%) of those from noncancer patients exceeded this level (P less than .03). In particular, effusions obtained from breast cancer patients showed a significantly higher level of TGF alpha, compared with those from noncancer patients (P less than .001). Effusions from 14 cancer patients also contained elevated levels of two tumor-associated antigens, CEA and/or TAG-72, and within this group, nine also had elevated levels of TGF alpha.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545892     DOI: 10.1093/jnci/81.15.1165

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  12 in total

1.  Epidermal growth factor-like activity and epidermal growth factor-receptors in human primary breast cancer.

Authors:  Z Kahán; M Szücs; M Vecsernyés; S Eckhardt
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 2.  EGF-related peptides in the pathophysiology of the mammary gland.

Authors:  N Normanno; F Ciardiello
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

Review 3.  The epidermal growth factor receptor as a target for therapy in breast carcinoma.

Authors:  J Baselga; J Mendelsohn
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

Review 4.  Epidermal growth factor-related peptides in the pathogenesis of human breast cancer.

Authors:  N Normanno; F Ciardiello; R Brandt; D S Salomon
Journal:  Breast Cancer Res Treat       Date:  1994-01       Impact factor: 4.872

Review 5.  The role of amphiregulin in breast cancer.

Authors:  D S Salomon; N Normanno; F Ciardiello; R Brandt; M Shoyab; G J Todaro
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

6.  MicroRNA-374b inhibits breast cancer progression through regulating CCND1 and TGFA genes.

Authors:  Yan Liu; Ai Zhang; Ping-Ping Bao; Li Lin; Yina Wang; Haijian Wu; Xiao-Ou Shu; Aiguo Liu; Qiuyin Cai
Journal:  Carcinogenesis       Date:  2021-04-30       Impact factor: 4.944

7.  Expression of transforming growth factor-alpha in primary human colon and lung carcinomas.

Authors:  C Liu; A Woo; M S Tsao
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

8.  Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas.

Authors:  C F Qi; D S Liscia; N Normanno; G Merlo; G R Johnson; W J Gullick; F Ciardiello; T Saeki; R Brandt; N Kim
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

9.  p53-dependent and p53-independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin.

Authors:  G R Merlo; F Basolo; L Fiore; L Duboc; N E Hynes
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

10.  The prognostic significance of transforming growth factors in human breast cancer.

Authors:  P A Murray; P Barrett-Lee; M Travers; Y Luqmani; T Powles; R C Coombes
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.